ipca
A dose of life

PRESS RELEASE

Ipca Laboratories Q2 FY15 Financial Results

Mumbai, November 10, 2014: Ipca Laboratories Limited today announced its unaudited standalone financial results for the second quarter and half year ended 30th September, 2014.

Key Financials of Q2 FY15

- Net Total Income down 7% at Rs. 789.31 crores.
- Indian formulations income up 19 % at Rs. 327.91 crores.
- Exports Income down 23% at Rs. 402.44 crores.
- EBIDTA margin @ 17.26 % as against @ 27.70% in Q2 FY14
- Net Profit at Rs. 61.30 crores down 53%.

Q2 FY15 at a glance			(Rs. Crores)
Particulars	**Q2 FY15**	**Q2 FY14**	**Growth**
Net Total Income	789.31	852.03	-7%
Export Income	402.44	522.25	-23%
EBITDA	134.77	234.53	-43%
EBIDTA Margin	17.26%	27.70%	-
Profit before Forex (gain) / loss and tax	98.13	208.91	-53%
Forex (gain) / loss	9.36	39.91	-
Net Profit after Forex (gain) / loss and tax	61.30	129.45	-53%
Earnings per share of Rs. 2/- each (Rs.)	4.86	10.26	-53%

Q2 FY15 Revenue break-up			(Rs. Crores)
Particulars	**Q2 FY15**	**Q2 FY14**	**Growth**
Formulations			
Domestic	327.91	276.17	19%
Exports	306.22	367.28	-17%
Total Formulations	**634.13**	**643.45**	**-1%**
APIs			
Domestic	44.52	40.49	10%
Exports	96.22	154.97	-38%
Total APIs	**140.74**	**195.46**	**-28%**
Grand Total	**774.87**	**838.91**	**-8%**

Ipca Laboratories Limited

Ipca Laboratories Ltd.
www.ipca.com
125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613
E: ipca@ipca.com CIN: L24239MH1949PLC007837

ipca A dose of life

Key Financials of H1 FY15

- Net Total Income up 4% at Rs. 1731.56 crores.
- Indian formulations income up 18% at Rs. 621.10 crores.
- Exports Income down 5% at Rs.973.31 crores.
- EBIDTA margin @ 21.30% as against @ 24.55 H1 FY14
- Net Profit at Rs. 206.79 crores up 3%.

H1 FY15 at a glance			(Rs. Crores)
Particulars	**H1 FY15**	**H1 FY14**	**Growth**
Net Total Income	1731.56	1662.04	4%
Export Income	973.31	1021.59	-5%
EBITDA	365.69	405.55	-10%
EBITDA Margin	21.30%	24.55%	-
Profit before Forex (gain) / loss and tax	291.71	353.14	-17%
Forex (gain) / loss	7.10	87.87	-
Net Profit after Forex (gain) / loss and tax	206.79	201.22	3%
Earnings per share of Rs. 2/- each (Rs.)	16.39	15.94	3%

H1 FY15 Revenue break-up			(Rs. Crores)
Particulars	**H1 FY15**	**H1 FY14**	**Growth**
Formulations			
Domestic	621.10	526.53	18%
Exports	693.95	700.03	-1%
Total Formulations	**1315.05**	**1226.56**	**7%**
APIs			
Domestic	108.66	86.12	26%
Exports	279.36	321.56	-13%
Total APIs	**388.02**	**407.68**	**-5%**
Grand Total	**1703.07**	**1634.24**	**4%**

About Ipca Laboratories:

Ipca is a fast growing pharmaceutical company with a strong thrust on exports which now account for 57% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.

Ipca Laboratories Limited

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Standalone Financial Results

Contact Information:
Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22- 6210 6051